Drug Trial Radar · NCT03863223
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
590
Actual
Start
Apr 22, 2019
Primary completion
Dec 30, 2022
Study completion Jul 30, 2024
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blinded, multicenter phase 3 clinical trial to evaluate the efficacy and safety of pyrotinib plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel in patients who have HER2 positive metastatic breast cancer and have not received systemic anticancer therapy for advanced disease.
Conditions
- Metastatic Breast Cancer
Interventions
Pyrotinib, Trastuzumab, DocetaxelDrug
Pyrotinib 400mg orally daily until progressive disease
Placebo, Trastuzumab, DocetaxelDrug
Placebo 400mg orally daily until progressive disease
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: Approximately 42 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Institute and Hospital,Chinese Academy of Medical Science
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.